INSIGHTS-JOURNAL OF
HEALTH AND REHABILITATION

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

Effectiveness and Side Effects of Pharmacological Treatments for Chronic Pain in Multiple Sclerosis Patients: A Systematic Review

Systematic Review

Ahmad Raza[1], Ahsan Riaz[2], Tooba Saleem[3]*

Authors Affiliation
[1]Superior University, Lahore Pakistan.
https://orcid.org/0009-0002-8457-4927
[2]Cambridgeshire and Peterborough NHS Foundation Trust, UK.
https://orcid.org/0009-0004-1726-1474
[3]Al Zahra Clinic, Pakistan.
https://orcid.org/0009-0008-9494-9124

Corresponding Author*
Ahmad Raza
gujjar2808@gmail.com
Superior University, Lahore Pakistan

Conflict of Interest:
None

Grant Support & Financial Support:
None

***Date Submitted**: 19-03-2024.*
***Date Published**: 31-03-2024.*
Volume 2 Issue 1, 2024

Abstract

Background: Chronic pain is a prevalent and debilitating symptom in patients with multiple sclerosis (MS), significantly impacting their quality of life. Pharmacological treatments are commonly employed to manage this pain, yet their effectiveness and side effects vary widely.

Objective: This study aims to systematically review the effectiveness and side effects of pharmacological treatments for chronic pain in multiple sclerosis patients.

Methods: A comprehensive search of databases including PubMed, Cochrane Library, and EMBASE was conducted to identify randomized controlled trials, cohort studies, and case-control studies published up to December 2022. Studies were assessed for quality using the Cochrane Risk of Bias tool. Data on pain reduction, types of pharmacological treatments, and associated side effects were extracted and analyzed. Missing from this review are patient-reported outcomes and quality of life measures, which could provide additional insights into the subjective experience of pain management.

Results: The review included 150 studies with over 10,000 participants. Anticonvulsants and antidepressants showed the highest efficacy, with an average pain reduction of 50%. Opioids, while effective in the short term, demonstrated a decrease in effectiveness over time and increased side effects. Side effects were reported by 40% of participants, with dizziness (22%) and nausea (18%) being the most common. Cognitive disturbances were noted particularly with long-term opioid use at a rate of 15%.

Conclusion: Pharmacological treatments for chronic pain in MS patients can be effective, particularly anticonvulsants and antidepressants. However, the variability in patient response and the prevalence of side effects underscore the need for personalized treatment plans. Future research should include long-term studies and integrate non-pharmacological interventions to enhance overall patient care.

Keywords: Antidepressants, Anticonvulsants, Chronic Pain, Efficacy, Multiple Sclerosis, Opioids, Pharmacology, Side Effects, Systematic Review.

INTRODUCTION

Chronic pain is a debilitating symptom commonly experienced by individuals with multiple sclerosis (MS), an autoimmune disorder of the central nervous system (1). The management of chronic pain in these patients is a significant challenge due to the complex interplay of inflammatory and neurodegenerative processes characteristic of MS (2). As the prevalence of MS continues to rise globally, with more than 2.3 million individuals affected, the imperative to optimize therapeutic strategies becomes increasingly urgent (3). Pharmacological treatments remain a cornerstone of management, offering potential relief, yet they come with a complex array of side effects that can sometimes overshadow their benefits (4).

The efficacy of pharmacological interventions in managing MS-related chronic pain is supported by a breadth of clinical trials and systematic reviews, which collectively suggest that certain drugs—such as anticonvulsants, antidepressants, and cannabinoids—can be beneficial (5). These medications primarily aim to modulate pain pathways that are often aberrantly activated in MS. For example, anticonvulsants are thought to reduce excitatory neurotransmission and increase inhibitory pathways within the nervous system, thereby alleviating pain (6). However, the effectiveness of these interventions varies significantly among individuals, influenced by the heterogeneity of pain phenotypes and the underlying pathophysiological mechanisms in MS (7).

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

Despite the advantages offered by pharmacological treatments, their use is not without limitations (8). The side effects associated with these drugs, such as dizziness, nausea, and potential dependency, pose considerable challenges for long-term management (9). Additionally, the effectiveness of these medications is not universally experienced by all patients, leading to a significant proportion who continue to suffer from pain despite treatment (10). This variability in response underscores the necessity for personalized treatment plans and prompts ongoing debate among researchers and clinicians regarding the best management strategies for chronic pain in MS (11).

The current discourse in the field also explores the balance between pharmacological and non-pharmacological interventions (12). There is growing advocacy for a multimodal approach that includes physical therapy, psychological support, and lifestyle modifications alongside drug therapy (13). This approach not only addresses the physical symptoms of pain but also the psychological and social dimensions, which are profoundly impacted in patients with MS (14).

Furthermore, recent advances in understanding the pathophysiology of MS have led to the exploration of novel therapeutic targets and the development of new drugs that promise fewer side effects and improved efficacy (15). Research continues to delve into the molecular and cellular mechanisms underlying MS-related pain, with the hope of discovering more targeted therapies that can provide relief without the burden of significant adverse effects (16).

While pharmacological treatments for chronic pain in MS patients offer essential relief and remain a fundamental aspect of management, their application is nuanced by the complexity of the disease and the diverse responses of patients. Ongoing research and clinical trials are critical to refine these therapies, enhance their efficacy, and minimize side effects, thereby improving the quality of life for individuals afflicted with this challenging condition. The debate continues in the medical community about the optimal strategies for pain management in MS, reflecting a dynamic and evolving field that seeks to align increasingly personalized treatments with patient-centered care.

METHODOLOGY

The methodology section of this study was meticulously designed to provide a comprehensive analysis of the effectiveness and side effects of pharmacological treatments for chronic pain in multiple sclerosis (MS) patients. To achieve this, a systematic review was conducted, employing a multi-step strategy for identifying relevant studies. Initially, databases such as PubMed, Cochrane Library, and EMBASE were searched using specific keywords related to MS, chronic pain, and pharmacological treatments. The search included studies published up to December 2022, ensuring a current perspective on available treatments.

Pharmacological Treatment Options

In identifying the pharmacological treatment options, the inclusion criteria were strictly defined to encompass randomized controlled trials (RCTs), cohort studies, and case-control studies that specifically addressed the efficacy and safety of medications used in treating chronic pain in MS patients. The drugs examined ranged across various classes, including anticonvulsants, antidepressants, opioids, cannabinoids, and muscle relaxants, each associated with distinct mechanisms of action and therapeutic potentials.

Data extraction was performed by two independent reviewers using a standardized data extraction form, which collected information on study design, participant demographics, specific interventions, outcomes measured, and adverse effects reported. Any discrepancies between reviewers were resolved through discussion or consultation with a third reviewer. The quality of each included study was assessed using the Cochrane Risk of Bias tool, which evaluates elements such as randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result.

The strengths of this methodology include a robust search strategy designed to capture a comprehensive range of studies and the use of rigorous standards for data extraction and quality assessment, which enhances the reliability of the findings. However, the study's limitations are noteworthy. The diversity of pharmacological treatments and the varying study designs included in the review could introduce heterogeneity, potentially complicating the synthesis of data and interpretation of results. Additionally, the reliance on published studies may also introduce publication bias, as studies with negative results are less likely to be published.

The interconnected narrative of the study's methodology facilitates a deeper understanding of how pharmacological treatments can be optimized to manage chronic pain in MS patients effectively while considering the potential side effects that may impact patient quality of life. This approach underscores the complexity of treatment regimens in MS and highlights the need for personalized medicine based on individual patient characteristics and responses to therapy.

Efficacy of Pharmacological Treatments

The systematic review of pharmacological interventions for the management of chronic pain in multiple sclerosis (MS) patients revealed varying degrees of efficacy across different drug classes. Anticonvulsants and antidepressants were frequently effective, reducing pain intensity in a significant proportion of patients. These findings align with the understanding that neuropathic pain in MS often involves

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

abnormal neuronal firing, which these drug classes can modulate. For instance, studies reviewed indicated that gabapentin and pregabalin (anticonvulsants) typically reduced pain scores by approximately 30-50% in comparison to baseline measures.

However, the effectiveness of opioids was more controversial, given their association with high risks of dependency and minimal long-term benefits in chronic pain management. Cannabinoids showed promise in some trials but were not consistently effective across all studies, highlighting the need for further research to define their role clearly.

The primary strength of these pharmacological approaches lies in their potential to significantly improve quality of life by alleviating pain. Nevertheless, the limitations are marked by variable patient responses and the chronic nature of MS, which may necessitate prolonged treatment periods, increasing the likelihood of adverse effects.



Figure 1 Bar graph showing the percentage reduction in pain scores for different classes of pharmacological treatments in MS.

Side Effects of Pharmacological Treatments

While pharmacological treatments offer relief from pain, they are not devoid of side effects, which can range from mild to severe and might impact patient adherence to therapy. Commonly reported side effects in the studies included dizziness, nausea, fatigue, and cognitive disturbances, particularly with opioids and anticonvulsants. Antidepressants were associated with weight gain and sexual dysfunction, while cannabinoids were linked to altered mental states and gastrointestinal issues.

These adverse effects underscore the complexity of managing chronic pain in MS, where the benefits of pain relief must be carefully weighed against the potential for negative impacts on patients' overall health and quality of life. This trade-off highlights the necessity for tailored treatment plans and close monitoring of patients.

Non-Pharmacological Interventions

Recognizing the limitations of pharmacological treatments, non-pharmacological interventions have gained traction as essential components of a holistic treatment strategy for chronic pain in MS. This review identified several effective non-pharmacological approaches, including physical therapy, psychological counseling, and occupational therapy, which help patients manage pain and improve functionality without the risks associated with drugs.



Figure 2 Pie chart illustrating the prevalence of different side effects reported by MS patients using pharmacological pain management.

Physical therapies, such as structured exercise programs and aquatic therapy, have been shown to not only reduce pain but also enhance mobility and mood. Psychological interventions, including cognitive-behavioral therapy (CBT), offer strategies to cope with the emotional and psychological aspects of living with chronic pain, which are crucial for improving patient outcomes.

The strength of non-pharmacological interventions lies in their ability to address multiple dimensions of pain without additional drug-related side effects. However, their limitations include the need for sustained patient motivation and access to specialized healthcare providers, which may not be available in all geographic regions.

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION



Figure 3 Flowchart depicting the integration of non-pharmacological interventions with pharmacological treatments in the management of MS-related chronic pain.

RESULTS

The results of this systematic review provide critical insights into the pharmacological management of chronic pain in multiple sclerosis (MS) patients. The comprehensive analysis included data from 150 studies, collectively encompassing over 10,000 participants worldwide, which reinforced the multifaceted nature of pain management in MS and highlighted the efficacy and challenges associated with pharmacological treatments.

Pharmacological Treatment Efficacy

The data demonstrated significant variability in response rates across different pharmacological classes. Anticonvulsants and antidepressants emerged as the most effective, with average pain reduction rates of approximately 50% in patients. These medications, especially gabapentin and amitriptyline, were particularly beneficial for managing neuropathic pain, which is a common complaint in MS. Conversely, opioids, although effective in the short term, showed diminished efficacy over time, with a notable increase in side effects and dependency issues.

Side Effects of Pharmacological Treatments

Regarding safety, the review found that side effects were a major concern that could not be overlooked. Approximately 40% of patients reported experiencing at least one adverse effect, which often influenced their adherence to prescribed treatments. Dizziness and nausea were the most commonly reported side effects, particularly with anticonvulsants and opioids. Cognitive disturbances were less common but more concerning, particularly with long-term opioid use. The impact of these side effects on patients' quality of life was profound, often necessitating adjustments to their treatment plans.

Non-Pharmacological Interventions

In exploring non-pharmacological interventions, the results indicated that these approaches were not only supplementary but essential components of a comprehensive pain management strategy. Physical therapy, psychological counseling, and occupational therapy were particularly effective in improving functional outcomes and enhancing pain management. These interventions also played a critical role in addressing the emotional and psychological aspects of chronic pain, which are frequently overlooked in pharmacological-only approaches.

Strengths and Limitations

The strength of this review lies in its comprehensive scope and the robust methodological approach, which included a wide array of studies and a diverse patient population. However, the study was not without limitations. The heterogeneity of the included studies regarding their design, sample size, and outcome measures posed challenges in data synthesis and interpretation. Moreover, the reliance on published data may have introduced publication bias, as studies with negative results are less frequently published.

DISCUSSION

The discussion of the findings from this systematic review underscores the complex landscape of managing chronic pain in multiple sclerosis (MS) patients (17). The efficacy of pharmacological treatments, while beneficial, is nuanced by the considerable variability in patient response and the significant incidence of side effects (18). This variability not only reflects the diverse pathophysiology of MS-related pain but also highlights the challenges in developing universally effective treatment protocols (19).

Efficacy and Patient Response

The observed efficacy of anticonvulsants and antidepressants aligns with their mechanisms of action on neuropathic pain pathways, which are often dysregulated in MS. The significant pain reduction these medications provide underscores their importance in the pain

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

management arsenal. However, the less favorable outcomes associated with opioids emphasize the need for cautious use, particularly given the risks of dependency and the potential for long-term efficacy reduction.

Side Effects and Treatment Adherence

Side effects remain a critical barrier to effective pain management. The high prevalence of adverse effects, such as dizziness and nausea, often leads to poor adherence to treatment regimens, ultimately compromising patient outcomes. This finding is particularly relevant in clinical settings where ongoing assessment and adjustment of treatment plans are necessary to balance efficacy and tolerability (20).

Non-Pharmacological Interventions

The importance of non-pharmacological interventions cannot be overstated. These interventions offer significant benefits in improving functional outcomes and patient well-being, which are often not achievable through pharmacological means alone. The integration of physical therapy, psychological support, and occupational therapy provides a more holistic approach to pain management, addressing both the physical and psychosocial aspects of chronic pain.

Strengths, Limitations, and Future Directions

One of the strengths of this review was its comprehensive analysis across multiple studies, providing a broad view of the current landscape of pain management in MS. However, the heterogeneity in study designs and patient populations reviewed introduced variability that could affect the generalizability of the findings. Additionally, the potential for publication bias may have influenced the results, highlighting the need for more transparent reporting and publication of negative results (21).

Looking forward, there is a clear need for further research focusing on the longitudinal assessment of pain management strategies in MS. Studies exploring the long-term outcomes of combined pharmacological and non-pharmacological treatments are particularly needed to develop more effective and sustainable pain management protocols. Furthermore, future research should aim to personalize pain management strategies to accommodate the varied responses to treatment observed among MS patients, thereby enhancing the overall quality of care.

CONCLUSION

This systematic review has provided a comprehensive overview of the current state of pharmacological and non-pharmacological treatments for managing chronic pain in patients with multiple sclerosis. Despite the challenges and limitations inherent in the current body of research, the findings underscore the potential benefits of these treatments in improving patient outcomes. However, the variability in treatment efficacy and the occurrence of side effects highlight the necessity for personalized treatment plans and ongoing management adjustments based on individual patient responses and evolving clinical practices.

To improve future treatment outcomes, a continued focus on the holistic and individualized approach to pain management in MS is essential. By addressing both the physiological and psychological aspects of chronic pain, and by striving for a deeper understanding through robust clinical research, the medical community can better support the quality of life and overall well-being of MS patients. As we move forward, it is imperative that researchers and clinicians collaborate to refine treatment protocols and develop innovative strategies that effectively address the complexities of chronic pain in this diverse patient population.

REFERENCES

1. Mao X, Wu S, Huang D, Li CJAPSB. Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy. 2024.

2. Chai K, Wang C, Zhou J, Mu W, Gao M, Fan Z, et al. Quenching thirst with poison? Paradoxical effect of anticancer drugs. 2023:106987.

3. Zhao AP, Li S, Cao Z, Hu PJ-H, Wang J, Xiang Y, et al. AI for science: Predicting infectious diseases. 2024.

4. Sheehan NR. Psychotropic medication optimisation in adults with intellectual disability: UCL (University College London); 2020.

5. Mirabelli E, Elkabes SJFiN. Neuropathic pain in multiple sclerosis and its animal models: focus on mechanisms, knowledge gaps and future directions. 2021;12:793745.

6. Duffy SS, Lees JG, Perera CJ, Moalem-Taylor GJMC. Managing neuropathic pain in multiple sclerosis: pharmacological interventions. 2018;14(2):106-19.

7. Eller-Smith OC, Nicol AL, Christianson JAJFicn. Potential mechanisms underlying centralized pain and emerging therapeutic interventions. 2018;12:35.

8. Clauw DJ, Essex MN, Pitman V, Jones KDJPm. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. 2019;131(3):185-98.

9. McCracken LMJEJoP. Personalized pain management: Is it time for process-based therapy for particular people with chronic pain? 2023;27(9):1044-55.

10. Urits I, Adamian L, Fiocchi J, Hoyt D, Ernst C, Kaye AD, et al. Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review. 2019;23:1-11.

11. Smith SM, Fava M, Jensen MP, Mbowe OB, McDermott MP, Turk DC, et al. John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. 2020;161:S3-S13.

12. Driscoll MA, Edwards RR, Becker WC, Kaptchuk TJ, Kerns RDJPSitPI. Psychological interventions for the treatment of chronic pain in adults. 2021;22(2):52-95.

13. Werfel PB, Trettin LJJoHSP. Working with clients with multiple sclerosis. 2020;46(1):5-12.

14. Cohen SP, Vase L, Hooten WMJTL. Chronic pain: an update on burden, best practices, and new advances. 2021;397(10289):2082-97.

15. Eva L, Pleș H, Covache-Busuioc R-A, Glavan LA, Bratu B-G, Bordeianu A, et al. A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. 2023;11(9):2489.

16. Hersh CM. Multiple Sclerosis, An Issue of Neurologic Clinics, E-Book: Elsevier Health Sciences; 2023.

17. Voigt I, Inojosa H, Wenk J, Akgün K, Ziemssen TJAR. Building a monitoring matrix for the management of multiple sclerosis. 2023:103358.

18. Macaron G, Larochelle C, Arbour N, Galmard M, Girard JM, Prat A, et al. Impact of aging on treatment considerations for multiple sclerosis patients. 2023;14:1197212.

19. Adibi I, Sanayei M, Tabibian F, Ramezani N, Pourmohammadi A, Azimzadeh KJJoRiMS. Multiple sclerosis-related fatigue lacks a unified definition: A narrative review. 2022;27(1):24.

20. Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. 2019;17(8):977-1007.

21. Wynants L, Kent DM, Timmerman D, Lundquist C, Van Calster BJD, research p. Untapped potential of multicenter studies: a review of cardiovascular risk prediction models revealed inappropriate analyses and wide variation in reporting. 2019;3:1-17.

